Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer

Journal of Korean Medical Science

Volumn 21, Issue 1, 2006, Pages 35-39

  Paik, Kwang Hyun ^a   Park, Yeon Hee ^a   Ryoo, Baek Yeol ^a   Yang, Sung Hyun ^a   Lee, Jae Cheol ^a   Kim, Cheol Hyun ^a   Ki, Seung Seog ^a   Kim, Jung Min ^a   Park, Myung Joon ^a   Ahn, Heui June ^a   Choi, Won ^a   Chung, Jin Haeng ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

bcl 2 Associated X Protein; Carcinoma, Small Cell; Ki 67 Antigen; Prognosis; Tumor Marker, Biological; Tumor Suppressor Protein p53

Indexed keywords

EID: 33144464656     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2006.21.1.35     Document Type: Article

References (39)

1. Ministry of Health and Welfare. 2002 Annual reports of the Korea Central Cancer Center Registry (Published in 2003); 29.
2. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 1991; 51: 5023-44.
3. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992; 66: 735-8.
4. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittleman WN, Hong WK. Expression of p53 oncoprotein in non-small cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995; 13: 1893-903.
5. Harpole DH, Herndon JE 2nd, Wolf WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res 1995; 55: 51-6.
6. Pezzella F, Turley H, Kuzu I, Tungerkar MF, Dunnil MS, Pierce CB, Harris A, Gatter KC, Mason DY. Bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 1993; 329: 690-4.
7. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small cell lung cancer. Br J Cancer 1995; 71: 1003-7.
8. Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 1997; 80: 1034-45.
9. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, Begg AC. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000; 89: 160-6.
10. Cagini L, Monacelli M, Giustozzi G, Moggi L, Bellezza G, Sidoni A, Bucciarelli E, Darwish S, Ludovini V, Pistola L, Gregorc V, Tonato M. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol 2000; 74: 53-60.
11. Tungekar MF, Gatter KC, Dunnil MS, Mason DY. Ki-67 immuno-staining and survival in operable lung cancer. Histopathology 1991; 19: 545-50.
12. Maitra A, Amirkhan RH, Saboorian MH, Frawley WH, Ashfaq R. Survival in small cell lung carcinoma is independent of Bcl-2 expression. Hum Pathol 1999; 30: 712-7.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij G, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
14. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995; 14: 3-15.
15. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
16. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828-31.
17. Laudanski J, Burzykowski T, Niklinska W, Chyczewski K, Furman M, Niklinski J. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. Lung Cancer 1998; 22: 191-200.
18. Mitsudomi T, Suzuki S, Yatabe Y, Nishio M, Kuwabara M, Gotoh K, Hatooka S, Shinoda M, Suyama M, Ogawa M, Takahashi T, Ariyoshi Y, Takahashi T. Clinical implications of p53 autoantibodies in the sera of patients with non-small cell lung cancer. J Natl Cancer Inst 1998; 90: 1563-8.
19. Bergqvist M, Brattstrom D, Larsson A, Holmertz J, Hesselius P, Losenberg L, Wagenius G, Brodin O. P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy; Anticancer Res 1998; 18: 1999-2002.
20. Rosenfeld MR, Malats N, Schramm L, Graus F, Cardenal F, Vinolas N, Rosell R, Tora M, Real FX, Posner JB, Dalmau J Serum anti-p53 antibodies and prognosis of patients with small cell lung cancer. J Natl Cancer Inst 1997; 89: 381-5.
21. Zalcman G, Tredaniel J, Schlichtholz B, Urban T, Milleron B, Lubin R, Meignin V, Couderc LJ, Hirsch A, Soussi T. Prognostic significance of serum p53 antibodies in patients with limited stage small cell lung cancer. Int J Cancer 2000; 89: 81-6.
22. Rodriguez-Salas N, Palacios J, Moreno G, de Castro J, Gonzalez-Baron M, Gamallo C. Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas. Lung Cancer 2001; 34: 67-74.
23. Gemba K, Ueoka H, Kiura K, Tabata M, Harada M. Immunohisto-chemical detection of mutant p53 protein in small cell lung cancer: relationship to treatment outcome. Lung Cancer 2000; 29: 23-31.
24. de Jong D, Prins FA, Mason DY, Reed JC, van Ommen GB, Kluin PM. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res 1994; 54: 256-60.
25. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17: 3225-36.
26. Cleary ML, Sklar J. Nucleotide sequence of a t (14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transeriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985; 82: 7439-43.
27. Harris AL. What does bcl-2 mean in solid tumors-friend or foe? Ann Oncol 1994; 5: 388-90.
28. Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994; 5 (Suppl 1): 61-5.
29. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-86.
30. Gaffney EF, O'Neil AJ, Staunton MJ. Bcl-2 and prognosis in non-small-cell lung carcinoma. N Engl J Med 1994; 330: 1757-8.
31. Kim YC, Park KO, Kim HJ, Choi IS, Park CS, Juhng SW. DNA ploidy and proliferative activity in bcl-2 expressed non-small cell lung cancer. Korean J Intern Med 1996; 11: 101-7.
32. Mathews MB, Bernstein RM, Franza BR Jr, Garreis JI. Identity of the proliferating cell nuclear antigen and cyclin. Nature 1984; 309: 374-6.
33. Landberg G, Ross G. Proliferating cell nuclear antigen and Ki-67 antigen expression in human hematopoietic cells during growth stimulation and differentiation. Cell Prolif 1993; 26: 427-37.
34. Wilson GD, Saunders MI, Dische S, Daley FM, Robinson BM, Martindale CA, Joiner B, Richman PI. Direct comparison of bromodeoxyuridine and Ki-67 labelling indices in human tumours. Cell Prolif 1996; 29: 141-52.
35. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-5.
36. Tubiana M, Courdi A. Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and longterm survival. Radiother Oncol 1989; 15: 1-18.
37. Scagliotti GV, Micela M, Gubetta L, Leonardo E, Cappia S, Borasio P, Pozzi E. Prognostic significance of Ki-67 labelling in resected non small cell lung cancer. Eur J Cancer 1993; 29: 363-5.
38. Wang DG, Johnston CF, Sloan JM, Buchanan KD. Expression of Bcl-2 in lung neuroendocrine tumors: comparison with p53. J Pathol 1998; 184: 247-51.
39. Mizera-Nyczak E, Dyszkiewicz W, Heider KH, Zeromski J. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer. Tumour Biol 2001; 22: 45-53.